Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

–   TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will host an Oncology program update for the investment community on Wednesday, May 31, 2023 in New York from 10:00 a.m. to 12:00 p.m. Eastern Time.

Ascendis Pharma to Host Oncology Program Update on May 31

COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormone deficiency, and host informational booth and events, at ECE 2023, the European Congress of Endocrinology being held May 13-16 in Istanbul, Turkey. ECE gathers international professionals to share the latest science and clinical practice across the fields of endocrinology and metabolism.

Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023

COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9.

Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference

The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's stock has soared Monday nonetheless.  The therapy, called TransCon OTH, is designed to treat adult patients with a disorder called hypoparathyroidism, in which the body produces abnormally low levels of parathyroid hormone.

Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data

Ascendis has seen a big uptake in sales for its human growth hormone therapy. The company said it plans to request a meeting with the FDA regarding hyperthyroidism therapy TransCon PTH.

Why Shares of Ascendis Pharma Are Climbing Monday

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript.

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript

• Focused on bringing TransCon™ PTH to the U.S. and EU markets as soon as possible • 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years, and U.S. Expanded Access Program continues to enroll new patients • SKYTROFA ® * revenue reached €31.6 million in the first quarter of 2023; Ascendis expects full-year 2023 SKYTROFA revenue of €150 - €160 million • Company to hold Oncology program update on Wednesday, May 31 in New York City • Conference call today at 4:30 pm ET COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2023 and provided a business update. “Based on our clinical experience with TransCon PTH to date, we have seen the improvement in the lives of many patients living with hypoparathyroidism and we are committed to working with regulatory authorities in the U.S. and EU to bring it to market as soon as possible,” said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer.

Ascendis Pharma Reports First Quarter 2023 Financial Results

NEW YORK , April 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the "Company") (NASDAQ: ASND). If you suffered losses exceeding $50,000 investing in Ascendis stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options

Ascendis Pharma: A Promising Diversification Play.

Ascendis Pharma: A Promising Diversification Play

NEW YORK , April 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ascendis Pharma A/S ("Ascendis" or the "Company") (NASDAQ: ASND).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ascendis Pharma A/S - ASND

Alnylam Pharmaceuticals

Apellis Pharma

argenx

BioMarin Pharmaceutical

Amicus Therapeutics

Horizon Pharma

Madrigal Pharmaceuticals

Sarepta Therapeutics

United Therapeutics

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

These Are the Top 10 Holdings of Avoro Capital Advisors

We are upgrading from a hold to buy rating for ASND following a 35% drop in stock price after FDA deficiency findings in the NDA for TransCon PTH for hyperparathyroidism. We expect potential US FDA approval delays beyond the April 30 PDUFA date but an eventual approval.

Ascendis Pharma: Recent FDA Setbacks Present A Buying Opportunity

COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, April 27, 2023, at 4:30 p.m. Eastern Time (ET) to review its first quarter 2023 financial results and provide a business update.

Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND) on behalf of Ascendis stockholders. Our investigation concerns whether Ascendis has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action.

ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm

The FDA found deficiencies with Ascendis' regulatory filing for TransCon PTH in treating hypoparathyroidism. Ascendis plans to talk with the FDA to learn more about the issues and hopefully address them.

Why Ascendis Pharma Stock Is Crashing This Week

Ascendis has enjoyed a market cap valuation of >$6bn thanks to its TransCon technology platform and single approved asset SKYTROFA. SKYTROFA is approved for growth hormone deficiency as a once-weekly injection. The current standard of care is a daily injection.

Ascendis Pharma: Is Dip On TransCon Application A Buy Opportunity?

NEW YORK--(BUSINESS WIRE)---- $ASND #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND). Investors who purchased Ascendis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/asnd. The investigation concerns whether Ascendis has violated federal securities laws.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation

The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.

Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies

LOS ANGELES--(BUSINESS WIRE)---- $ASND #ASND--The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

The FDA has identified deficiencies in Ascendis' regulatory filing for the hypoparathyroidism candidate TransCon PTH. With little info on the nature of the deficiencies, investors are moving to the sidelines today.

Why Ascendis Pharma Stock Is Plunging Today

The FDA decision prevents Ascendis from labeling and marketing the new drug application for TransCon PTH. ASND stock plunged.

Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug Application

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Ascendis Pharma (NASDAQ: ASND) resulting from allegations that Ascendis may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ascendis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

News for Ascendis Pharma Stock (ASND)